EN DE
Watch Lasa Supergenerics Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lasa Supergenerics Limited (LASA) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Lasa Supergenerics Limited stock ₹4.16, price ₹4.22, that is 1.4% below the price, quality 30 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE670X01014

LS Lasa Supergenerics Limited logo Thin data Nov 10, 2026

Lasa Supergenerics Limited

LASA · NSE

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value ₹4.16 · Fairly valued 
Quality 30/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −34.1 %/yr in INR) 
Loss-making · -135.6% net margin (FY2026) 
Negative free cash flow 
Trails peers (3/9) 
Narrow moat 9/100
Thin data 
Estimate
Watch Lasa Supergenerics Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹85.60 ₹4.22 Fair Value ₹4.16 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range ₹4.22 – ₹85.60 · fair‑value band ₹3.12 – ₹5.20 · the ₹4.22 price screens above the ₹4.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Lasa Supergenerics in your weekly email

Every Wednesday you see whether Lasa Supergenerics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India.

Show moreShow less

It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products.

The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.

Stock analysis

Lasa Supergenerics Limited (LASA) currently trades at ₹4.22, while our estimate is ₹4.16, so the stock looks roughly fairly valued today (gap 1.4%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₹3.12 (bear) to ₹5.20 (bull), the price of ₹4.22 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Lasa Supergenerics Limited reported revenue of ₹251M in FY2026 versus ₹1.4B in FY2022, a compound −34.6%/yr. Reported net income was −₹341M in FY2026.

Key figures

Market cap ₹211M (≈ $2.2M) Micro · P/S ratio 3.59 · EPS (TTM) ₹−0.8000 · Net margin −136% · Return on equity −51.1% · Return on assets (EBIT) −8.3% (5-year average) · Operating margin −216% · Revenue growth (YoY) −93.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 65% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −1%, LASA screens cheaper than that median.

Fair Value

Bear ₹3.12 Fair Value ₹4.16 Bull ₹5.20
Price ₹4.22 · Downside -1.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 48
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 64
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−82.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−42.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.1%
Start year 2021 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.5% (2021) → −53.2% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch LASA, get fair value alerts →

Compare Lasa Supergenerics Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 603 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −1.4% · Above median
Profitability
Return on assets −51.2% · Bottom 25%
Net margin (12 months) −135.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −93.4% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.43× · Cheapest 25%
P/S (12 months) 3.24× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)31 · sector 19
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.96 $113.53 +37% vs LASA
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.07 ¥53.04 +10% vs LASA
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,880 ₹1,983 +5% vs LASA
Haleon plc HLN $9.09 $8.62 −5% vs LASA
Merck KGaA MRK €149.60 €108.83 −27% vs LASA
Galderma Group GALD CHF 191.40 CHF 111.92 −42% vs LASA
Takeda Pharmaceutical Company TAK $21.12 $11.34 −46% vs LASA
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs LASA
Teva Pharmaceutical Industries Limited TEVA $43.65 $20.74 −52% vs LASA
Divi's Laboratories Limited DIVISLAB ₹11,442 ₹1,567 −86% vs LASA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lasa Supergenerics Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Lasa Supergenerics Limited Fair Value". https://www.fairvalue-calculator.com/stock/LASA

Frequently asked questions

Is Lasa Supergenerics Limited (LASA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is ₹4.16 versus a price of ₹4.22, about 1% lower (fairly valued).
What is the fair value of LASA?
Our estimate for Lasa Supergenerics Limited is ₹4.16 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹4.22.
What is the quality score of LASA?
Lasa Supergenerics Limited has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lasa Supergenerics Limited (LASA)?
Our calculated price target is the estimate of ₹4.16 (as of Nov 10, 2026). Cautious scenario ₹3.12, optimistic scenario ₹5.20. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Lasa Supergenerics Limited stock forecast for 2026?
Our estimate puts fair value at ₹4.16, about 1% lower versus a price of ₹4.22 (fairly valued). Cautious scenario ₹3.12, optimistic scenario ₹5.20. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Lasa Supergenerics Limited (LASA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lasa Supergenerics Limited it is ₹4.16 per share (as of Nov 10, 2026), against a price of ₹4.22.
Is Lasa Supergenerics Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, LASA trades above its calculated fair value: price ₹4.22, fair value ₹4.16, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LASA?
No. The price is what the market pays today (₹4.22); the fair value is what the company's own numbers justify (₹4.16). For Lasa Supergenerics Limited the two are ₹0.0600 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lasa Supergenerics Limited worth?
The market values Lasa Supergenerics Limited at about ₹211M (market capitalisation, as of Nov 10, 2026). Per share that is ₹4.22; our models calculate a fair value of ₹4.16 per share.
What do the bullish and bearish scenarios say about LASA?
Our models span a range for Lasa Supergenerics Limited: cautious scenario ₹3.12, base ₹4.16, optimistic ₹5.20 per share (as of Nov 10, 2026, price ₹4.22). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lasa Supergenerics Limited (LASA)?
Balance-sheet figures for Lasa Supergenerics Limited (as of Nov 10, 2026): return on equity −51.1%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is LASA from its 52-week high?
Lasa Supergenerics Limited trades at ₹4.22, about 65% below its 52-week high of ₹12.04 and at the low of ₹4.22 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹4.16 is for.
Which stocks are comparable to Lasa Supergenerics Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lasa Supergenerics Limited stock attractive at the current price?
The data as of Nov 10, 2026: price ₹4.22, calculated fair value ₹4.16 (−1%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Lasa Supergenerics Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lasa Supergenerics Limited (LASA)?
The closing price on Nov 9, 2026 was ₹4.22. Our estimate is ₹4.16, about 1% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lasa Supergenerics Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Lasa Supergenerics Limited

How large is the market capitalisation of Lasa Supergenerics Limited (LASA)?
The market capitalisation of Lasa Supergenerics Limited is ₹211M (≈ $2.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lasa Supergenerics Limited (LASA)?
The price-to-sales ratio of Lasa Supergenerics Limited is 3.59 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lasa Supergenerics Limited (LASA)?
Earnings per share at Lasa Supergenerics Limited are ₹−0.8000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lasa Supergenerics Limited (LASA)?
The net margin of Lasa Supergenerics Limited is −136% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lasa Supergenerics Limited (LASA)?
The return on equity (ROE) of Lasa Supergenerics Limited is −51.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lasa Supergenerics Limited (LASA)?
On an EBIT basis the return on assets of Lasa Supergenerics Limited is −8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lasa Supergenerics Limited (LASA)?
The operating margin of Lasa Supergenerics Limited is −216% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lasa Supergenerics Limited (LASA)?
Revenue at Lasa Supergenerics Limited is growing −93.4% versus a year earlier (3y avg −42.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lasa Supergenerics Limited (LASA)?
Earnings per share at Lasa Supergenerics Limited are growing +225% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Lasa Supergenerics Limited (LASA) generate?
The free cash flow of Lasa Supergenerics Limited is −₹737K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lasa Supergenerics Limited (LASA) carry?
The net debt of Lasa Supergenerics Limited is ₹90.5M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Lasa Supergenerics Limited in the live analysis

One click puts Lasa Supergenerics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.